These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36877052)

  • 1. Drug-Resistant Tuberculosis on the Balkan Peninsula: Determination of Drug Resistance Mechanisms with Xpert MTB/XDR and Whole-Genome Sequencing Analysis.
    Truden S; Sodja E; Žolnir-Dovč M
    Microbiol Spectr; 2023 Mar; 11(2):e0276122. PubMed ID: 36877052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
    Pillay S; Steingart KR; Davies GR; Chaplin M; De Vos M; Schumacher SG; Warren R; Theron G
    Cochrane Database Syst Rev; 2022 May; 5(5):CD014841. PubMed ID: 35583175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance evaluation of the Xpert MTB/XDR test for the detection of drug resistance to
    Omar SV; Louw G; Ismail F; Liu X; Ngcamu D; Gwala T; van der Meulen M; Joseph L
    J Clin Microbiol; 2024 Aug; 62(8):e0022924. PubMed ID: 39058018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum.
    Cao Y; Parmar H; Gaur RL; Lieu D; Raghunath S; Via N; Battaglia S; Cirillo DM; Denkinger C; Georghiou S; Kwiatkowski R; Persing D; Alland D; Chakravorty S
    J Clin Microbiol; 2021 Feb; 59(3):. PubMed ID: 33298611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of the Xpert
    Maya T; Wilfred A; Lubinza C; Mfaume S; Mafie M; Mtunga D; Kingalu A; Mgina N; Petrucka P; Doulla BE; Ngadaya E; Mfinanga SG; Mnyambwa NP
    BMC Infect Dis; 2024 Jul; 24(1):672. PubMed ID: 38965482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study.
    Penn-Nicholson A; Georghiou SB; Ciobanu N; Kazi M; Bhalla M; David A; Conradie F; Ruhwald M; Crudu V; Rodrigues C; Myneedu VP; Scott L; Denkinger CM; Schumacher SG;
    Lancet Infect Dis; 2022 Feb; 22(2):242-249. PubMed ID: 34627496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Xpert
    Katamba A; Ssengooba W; Sserubiri J; Semugenze D; William KG; Abdunoor N; Byaruhanga R; Turyahabwe S; Joloba ML
    medRxiv; 2023 Apr; ():. PubMed ID: 37066316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.
    Theron G; Peter J; Richardson M; Barnard M; Donegan S; Warren R; Steingart KR; Dheda K
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010705. PubMed ID: 25353401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa.
    Oostvogels S; Ley SD; Heupink TH; Dippenaar A; Streicher EM; De Vos E; Meehan CJ; Dheda K; Warren R; Van Rie A
    Microb Genom; 2022 Apr; 8(4):. PubMed ID: 35471145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Xpert MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda.
    Katamba A; Ssengooba W; Sserubiri J; Semugenze D; Kasule GW; Nyombi A; Byaruhanga R; Turyahabwe S; Joloba ML
    PLoS One; 2023; 18(8):e0284545. PubMed ID: 37590288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients.
    Chen X; Li R; Ge S; Li Y; Cai C; Weng T; Zhang Y; Jiang J; Feng Z; Chen Y; Zhang Y; Ma J; Persing DH; Chen J; Tang YW; Sun F; Zhang W
    J Clin Microbiol; 2023 Jun; 61(6):e0183222. PubMed ID: 37249422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.
    Heyckendorf J; Andres S; Köser CU; Olaru ID; Schön T; Sturegård E; Beckert P; Schleusener V; Kohl TA; Hillemann D; Moradigaravand D; Parkhill J; Peacock SJ; Niemann S; Lange C; Merker M
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of novel
    Valafar F; Ramirez-Busby SM; Torres J; Paul LV; Rodwell TC; Victor TC; Rodrigues C; Gler MT; Crudu V; Catanzaro T
    Int J Mycobacteriol; 2015 Mar; 4(Suppl 1):51-52. PubMed ID: 27695670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of isoniazid and ethionamide cross-resistance by whole genome sequencing and association with poor treatment outcomes of multidrug-resistant tuberculosis patients in South Africa.
    Malinga L; Brand J; Jansen van Rensburg C; Cassell G; van der Walt M
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S36-S37. PubMed ID: 28043598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TB drug susceptibility testing in high fluoroquinolone resistance settings.
    Saluzzo F; Masood F; Batignani V; Di Marco F; Majeed U; Ghazal A; Cirillo DM; Tahseen S
    IJTLD Open; 2024 May; 1(5):230-235. PubMed ID: 39022777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Characterization Conferred Co-Resistance to Isoniazid and Ethionamide in
    Cao B; Mijiti X; Deng LL; Wang Q; Yu JJ; Anwaierjiang A; Qian C; Li M; Fang DA; Jiang Y; Zhao LL; Zhao X; Wan K; Liu H; Li G; Yuan X
    Infect Drug Resist; 2023; 16():3117-3135. PubMed ID: 37228658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of efflux pump genes in extensively drug-resistant isolates of Mycobacterium tuberculosis.
    Kanji A; Hasan R; Zhang Y; Shi W; Imtiaz K; Iqbal K; Shafiq S; Hasan Z
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S150. PubMed ID: 28043519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Discordance between Genotypic and Phenotypic Assays for Rifampicin-Resistant
    Bokop C; Faye LM; Apalata T
    Pathogens; 2023 Jul; 12(7):. PubMed ID: 37513756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the MolecuTech
    Cho EJ; Kang MR; Kim JH; Lee JI; Son ES; Park CH; Aung WW; Lee JS
    Int J Tuberc Lung Dis; 2022 Sep; 26(9):869-874. PubMed ID: 35996285
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.
    Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM
    BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.